Clinical trial
Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent…
NCT00362921 · Duke University, Other · Completed
Key facts
| NCT number | NCT00362921 |
|---|---|
| Title | Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent Glioblastoma Multiforme |
| Official title | Phase II Trial of Gliadel Plus 06-Benzylguanine for Patients With Recurrent Glioblastoma Multiforme |
| Lead sponsor | Duke University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Adult Brain Tumor |
| Intervention type | Drug |
| Interventions | Gliadel wafers in combination with O6-benzylguanine |
| Enrollment | 52 |
| Start date | Apr 1, 2004 |
| Primary completion | Aug 1, 2007 |
| Completion | Jul 1, 2008 |
| First posted | Aug 15, 2006 |
| Last update posted | Jul 10, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: